Goldman Sachs: Expects JD Health's (06618.HK) second quarter revenue to be stable, maintains "buy" rating.

Financial news app Zhitong learned that Goldman Sachs released a research report, stating that for the second quarter of this year, Jingdong Health (06618.HK) is expected to have steady revenue while maintaining strict expenses. They maintained a "buy" rating on the stock, reflecting Jingdong Health's strong position and revenue visibility in the pharmacy and medical services field.